For the Inventor, By the Inventor

Enter assignee name

Vancouver, Canada

Qlt Inc.

USPTO Granted Patents = 35

% Expired Patents = 45.7

CIPO Patents = 16

EPO Patents = 4

Forward Citations = 380

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

H Andrew Strong (7 out of 13 patents)

Julia G Levy (7 out of 46 patents)

Anna M Richter (5 out of 25 patents)

4. Janice North (5 out of 8 patents)

5. David W C Hunt (4 out of 9 patents)

6. Zaihui Zhang (4 out of 50 patents)

7. Timothy Scott Daynard (4 out of 16 patents)

8. Ronald Erwin Boch (4 out of 10 patents)

9. Alan R Rapacki (3 out of 35 patents)

10. Shisen Wang (3 out of 12 patents)

11. Philippe Maria Clotaire Margaron (3 out of 7 patents)

12. Valery Rubinchik (2 out of 12 patents)

13. Gregory B Chopiuk (2 out of 11 patents)

14. Mohammad Azab (2 out of 2 patents)

15. Troy Albert Reaves, Jr (2 out of 2 patents)

Core Competencies:

Photodynamic Therapy

Visual Disorders

Macular Degeneration

Inflammatory Diseases

Drug Delivery

Lacrimal Implants

Cancer Treatment

Retinoid Deficiency

Oculoselective Drugs

Angiogenesis Inhibition

Photosensitive Drugs

ILK Inhibitors

35 patents: Sort by Forward Citations

1. 9173856 - Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency (2015-11-03),

2. 8333726 - Lacrimal implants and related methods (2012-12-18),

3. 8210902 - Surface treated implantable articles and related methods (2012-07-03),

4. 8158669 - Method for treating neovascularization (2012-04-17),

5. 8106038 - Method for reducing or preventing PDT related inflammation (2012-01-31),

6. 8034803 - Photodynamic therapy of occult age-related macular degeneration (2011-10-11),

7. 7998497 - Nasolacrimal drainage system implants for drug therapy (2011-08-16),

8. 7922702 - Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device (2011-04-12),

9. 7863429 - Treatment of inflammatory diseases including psoriasis (2011-01-04),

10. 7850981 - Immuno-adjuvant PDT treatment of metastatic tumors (2010-12-14),

11. 7753943 - Reduced fluence rate PDT (2010-07-13),

12. 7678829 - Oculoselective drugs and prodrugs (2010-03-16),

13. 7678775 - ILK inhibitors for the treatment of renal disease (2010-03-16),

14. 7504228 - Integrin linked kinase modulation of monocyte activation (2009-03-17),

15. 7479503 - Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases (2009-01-20),

Company Overview

QLT Inc., based in Vancouver, Canada, is a biotechnology company focused on the development of innovative therapies for various medical conditions. The organization specializes in drug delivery systems and photodynamic therapy, leveraging advanced technologies to enhance treatment efficacy. QLT's research initiatives are primarily centered around improving patient outcomes through targeted therapies, with a commitment to addressing unmet medical needs in the healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

35 Patents

#20 in Vancouver

#384 in Canada

#19,168 in the World

Vancouver, Canada

Qlt Inc.

Forward Citations = 380

70 inventors:

H Andrew Strong (7 out of 13 patents)

Julia G Levy (7 out of 46 patents)

Anna M Richter (5 out of 25 patents)

4. Janice North (5 out of 8 patents)

5. David W C Hunt (4 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Qlt Inc.. Retrieved from https://idiyas.com/company/qlt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…